Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 43,36€ (+148,91%). La mediana es de 43,36€ (+148,91%).
| Comprar |
6 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
Semler Scientific files supplemental pro-forma financial data for merger with Strive
Semler Scientific filed amended, unaudited consolidated pro-forma financial data with the SEC for the nine months ended September 30, 2025 and for 2024 in connection with the proposed stock transaction with Strive. The company continues to emphasize customary closing conditions and cites risk factors such as bitcoin volatility, integration risks, potential delays, legal proceedings and dilution from additional Strive shares. Semler released preliminary Q3 2025 figures (revenue guidance $6.9–7.5 million; operating expenses $12.8–13.4 million), reported an unrealized fair‑value gain of about $30 million on bitcoin holdings (carrying value $575.8 million as of Sept. 30) and announced a $20 million credit facility with Coinbase Credit. » Más en de.investing.com
Semler Scientific uses dashboard to disclose and adjusts metrics for bitcoin strategy
Semler Scientific names bitcoin return as its key metric and reports a Q3 2025 return of 0.9% and a year-to-date return (through 10 Nov 2025) of 30.6%. The company operates a public dashboard with market data, bitcoin purchases and performance metrics and intends to use it to comply with Regulation FD. Semler warns of risks from bitcoin volatility, its treasury strategy and the health-care business and reports holding 5,048 bitcoins with an unrealized gain of about $30 million. In addition, the company provides preliminary Q3 figures (revenue guidance $6.9–7.5m, operating expenses $12.8–13.4m), a $20 million loan from Coinbase Credit secured by bitcoin and an ongoing merger with Strive, Inc. » Más en de.investing.com
Semler Scientific files supplemental SEC disclosure on merger with Strive
Semler Scientific said it filed a supplemental disclosure (Form 8‑K, Exhibit 99.1) related to the proposed all‑stock transaction with Strive, which remains subject to shareholder approval and customary closing conditions. The filing includes a risk warning such as possible failure of the transaction, litigation, integration challenges, dilution, and potential stock‑price and customer or employee reactions. The company also released preliminary Q3 figures (revenue guidance $6.9–7.5 million; operating expenses $12.8–13.4 million) and reported an unrealized Bitcoin gain of about $30 million; its Bitcoin holdings (5,048 BTC) were valued at $575.8 million and it took a $20 million loan from Coinbase Credit secured by Bitcoin. Benchmark cut its price target to $86 but kept its rating at Buy. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | sep 2025 | |
|---|---|---|
| Ingresos | 6,38M | - |
| Beneficio bruto | 5,84M | - |
| Beneficio neto | 14,40M | - |
| EBITDA | 21,70M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 266,83M€ |
Número de acciones | 15,29M |
Máximo/mínimo de 52 semanas | 56,66€ - 12,78€ |
| Dividendos | No |
Beta | 1,32 |
Ratio P/E | 184,82 |
Ratio PEG | −0,38 |
Ratio P/B | 0,66 |
Ratio P/S | 12,66 |
Perfil de la empresa
Semler Scientific, Inc. bietet Technologielösungen zur Verbesserung der klinischen Effektivität und Effizienz von Gesundheitsdienstleistern in den Vereinigten Staaten an. Zu den Produkten des Unternehmens gehört QuantaFlo, ein vierminütiger In-Office-Blutfluss-Test, der es Gesundheitsdienstleistern ermöglicht, Blutflussmessungen als Teil ihrer Untersuchungen des Gefäßzustands eines Patienten durchzuführen. Die Produkte des Unternehmens werden von Kardiologen, Internisten, Nephrologen, Endokrinologen, Podologen und Hausärzten sowie von Krankenversicherungen, integrierten Versorgungsnetzen, unabhängigen Ärztegruppen und Unternehmen, die Verträge mit dem Gesundheitswesen abschließen, wie z. B. Risikobewertungsgruppen, genutzt. Das Unternehmen bietet seine Produkte über Vertriebsmitarbeiter und Händler an. Semler Scientific, Inc. wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Santa Clara, Kalifornien.
| Nombre | SEMLER SCIENTIFIC |
| CEO | Douglas Murphy-Chutorian |
| Sede | Santa Clara,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 21/02/2014 |
| Empleados | 79 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | SMLR |
Frankfurt | 6FA.F |
Düsseldorf | 6FA.DU |
München | 6FA.MU |
Descubrir activos
Los accionistas de SEMLER SCIENTIFIC también invierten en los siguientes activos


